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ABSTRACT
Cancer is the uncontrolled growth of abnormal cells in the body. It is the most serious disease on which extensive research 
is being done all over the world. Structure based drug designing offers a computational approach to identify the potential 
leads which can be developed into a drug. The In-Silico study of the current work aimed at inhibiting the three major targets 
of cancer by a natural compound Andrographolide from Andrographis paniculata. This exhibited a minimal energy against 
the targets hence suggesting the stability of the compound. Comparison studies of the compound with the already available 
anti-cancer  drugs  and  enzyme  inhibitors,  stated  that  andrographolide  is  efficient  to  act  on  the  targets  by  exhibiting 
promising  interactions and good scores. This was also found to obey the Lipinski’s Rule of 5 and computed ADMET 
properties showed the drug likeliness and improved bioavailability. Since it is from a natural source the compound is non 
toxic and has reduced side effects. 
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INTRODUCTION
Structure-based virtual screening and post-screening analysis 
are  emergent  tasks  in  computer-based  drug  discovery. 
Combining these two methods to effectively reduce the false 
positives from a large compound database is considered as a 
key  step  to  finding  the  lead  compounds.  Various  signal 
transduction  pathways  are  involved  in  regulation  of  cell 
growth,  thus  their  impairment  may  be related  to  tumor 
pathogenesis.  Phosphorylation  is  the  most  important 
reversible mechanism for triggering or inhibiting the activity 
of specific proteins in a signaling pathway. This fundamental 
process is  achieved  through  the activity  of  various  protein 
kinases. The first anticancer agent specifically targeted to a 
protein kinase was Imanitib, which acts as an inhibitor of the 
oncogenic  kinase  BCR-Abl  and  is  active  in  the  chronic 
myelogenous  leukemia.
[1] The  first  intracellular  second 
messenger was described in the late Fifties as adenosine 3’5’-
cyclic monophosphate (cyclic AMP, cAMP).
[2]
It is present in every cell, where it is synthesized by adenylyl 
cyclase  from  ATP,  and  is  hydrolyzed  by  cAMP-specific 
phosphodiesterases  to  adenosine  5’- monophosphate.  The 
rate  of cAMP production  and degradation is sensitive to a 
wide range of extracellular and intracellular signals, such that 
cAMP can directly regulate a variety of cell functions, from 
metabolism to ion channel activation, cell growth and 
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differentiation, gene expression and apoptosis.
[3] Within each
cell,  cAMP  may  activate  different  proteins.  PKA  are 
ubiquitous intracellular cAMP effectors that regulate multiple 
processes.  Their  target  is  specified  by  their  intracellular 
localization, obtained through anchoring at specific sites in 
macromolecular  complexes,  and  through  the  expression  of 
specific subunits.
During  cancer  pathogenesis,  the  normal  cell  activity  is 
imbalanced via mutation of selected proteins, or by altering 
their rate of synthesis/degradation, or by affecting the activity 
of otherwise normal proteins. Given the involvement of PKA 
in several different intracellular functions, it is conceivable 
that  pathological  processes  may  affect  the  cAMP/PKA 
pathway.  Indeed,  several  converging  data  reveal  that  the 
cAMP/PKA signaling pathway is altered in different cancers, 
and may be exploited for cancer diagnosis and/or therapy.
[4-
5] Epidermal growth factor receptor (EGFR) is a member of 
the  receptor  tyrosine  kinase  family,  and  overexpression  of 
EGFR is associated with poor prognosis and progression of 
many human cancers, including oral cancer.
[6]
At the molecular level, stimulation of EGFR induces intrinsic 
tyrosine kinase activity and cellular signaling that results in 
cell  growth  and  proliferation. Andrographis  paniculata
(Acanthaceae)  is  one of the  most  valuable medicinal  plant 
and  bio-factory  of  diterpronidlactons  which  have  immense 
value  like  immune  stimulating,  anti  – inflammatory,  anti-
fertility, liver  protection, anti-HIV  and  bile  secrecation 
stimulating agent.
[7]
A  number  of  active  components are  reported  in  this  plant 
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polyphenols. 
[8-9] However,  the  most  pharmacological 
properties  present  in  active  principle  of  andrographolide.  
The  present  study  focused  on  In-Silico analysis  of 
andrographolide against cancer.
MATERIALS AND METHODS
Target  Identification:  The  targets  were  selected  the  3 
Dimensional  structures  of  the  target  proteins  Epidermal 
growth  factor  receptor  complexed  with  erlotinib  (Fig.  1 
PDBID  – 1M17),  Human  Abl  kinase  in  complex  with 
nilotinib  (Fig.  2 PDBID- 3CS9)  and  Human  cAMP 
dependent protein kinase (PDB ID-30VV) were downloaded 
from  the  online  protein  structure  repository,  Protein  Data 
Bank  (PDB).  The  structures  were  determined  by  Xray 
Diffraction method and had ligands coupled in the binding 
site. 
Fig. 1: The Crystal structure of the targets 1M17
Fig. 2: The Crystal structure of the targets 3CS9
Fig. 3 The Crystal structure of the targets 3OVV
Preparation  of  compounds:  The  structures  of  the 
compounds  andrographolide  and  three  current  anti-cancer 
drugs were downloaded from Pubchem in SDF format and 
converted to PDB format using the tool MARVIN SKETCH 
(http://www.chemaxon.com/marvin/sketch/index.php).  The 
compound structures were energy minimized and considered 
for docking studies. The original ligands of the targets were 
also prepared similarly and taken for docking.
Molecular  Docking: Graphical-Automatic  Drug  Design 
System for Docking, Screening and Post-Analysis program 
iGEMDOCK  was  used  to  gain  the  docking  results  of  the 
listed  compounds  with  the  target.  The  binding  site  of  the 
target  was prepared  and the  energy minimized compounds 
were  imported.  The  docking  protocol consisted  of  25 
generations per ligand and the population size of 100 random 
individuals. All the docking conformations were performed 
twice using genetic evolutionary algorithm and the fitness of 
the  docked  structures  were  calculated.    The  hydrophobic 
preference and electrostatic preference were set to 1.00. The 
binding site of the target was identified at a distance 8Å. The 
empirical scoring function of iGEMDOCK was estimated as:  
Fitness = vdW + Hbond + Elec. 
Here, the vdW term is van der Waal energy. Hbond and Elect 
terms  are  hydrogen  bonding  energy  and  electro  statistic 
energy, respectively.
Drug likeliness and Bioavailability: It is important for any 
compound to obey the Lipinski’s rule of five
[10] in order to 
be  formulated  as  a  drug
. The  Absorption Distribution, 
Metabolism, Elimination and Toxicity (ADMET) parameters 
are much significant for a drug to be available to the system. 
MedChem  Designer 
[11] is  a  tool  that  instantly  generates 
predicted  values  of  key  ADMET  properties:  LogP 
(Hydrophillicity), LogD  (permeability),  Topological  Polar 
Surface  Area,  Molecular  weight,  HBDH,  HBA  (N+O  as 
M_NO),  and  Rule  of  5.  The  ADMET  properties  of  the 
compounds  were  computed  and  the  drug  likliness  is 
evaluated.
RESULTS AND DISCUSSION
Docking simulations of andrographolide with three different 
targets  for  cancer  resulted  in  better  interactions  than  the 
commercially available cancer drugs.
Docking of andrographolide with the target 3CS9
The  original  ligand bound  to  the target exhibited a  fitness 
score of -80.44 and interacted with the active site residues 
Glu266,  Asp381,  Glu282,  Lys285,  Lys266,  Arg362  and 
Asp361. The compound andrographolide exhibited a fitness 
score  of  -76.06  and  interacted  with  the  residues  Ser500, 
Lys285, Glu296, Val289, Asp381 and Arg362 at the active 
site. This shows good interaction and efficient score than the 
available drugs (Table I). 
Docking of andrographolide with the target 3OVV
The original ligand 1SB bound to the target 3OVV exhibited 
a fitness score of -60.06 and interacted with the active site 
residues  Thr51,  Asn20 and  Tyr330.  The  compound 
andrographolide  ehibited  a  fitness  score  of  -71.35  and 
interacted  with the  residues  Thr51,  Asn20,  Tyr330  Arg93, 
Trp30,  Arg93,  Arg190  and  Lys192  at  the  active  site  of 
3OVV.  The  compound  exhibits  minimum energy  than  the 
ligand  and  interacts  well  at  the  binding  pocket.  This  also 
shows good interaction and efficient score than the available 
drugs (Table II).
Docking of andrographolide with the target 1M17
The  original  ligand  erlotinib  bound  to  the  target  1M17 
exhibited  a  fitness  score  of  -62.37 and  interacted with the 
active site residues Tyr740, Leu838, Glu673 and Ala674. Sharmila et al. / In-Silico Analysis of Andrographolide…..……
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Table I: Interaction of andrographolide and the available drugs with 3CS9
S. No Compound Energy vdW H Bond Elec Interacting residues
1 Ligand-Nilotinib -80.44 -71.22 -9.22 0
Glu266
Asp381
Glu282
Lys285
Lys266
Arg362
Asp361
2 Drug-sorafenib -88.02 -79.09 -8.93 0
His361
Asp381
Lys285
Glu286
Val289
3. Drug-imatinib -77.56 -65.06 -12.5 0
His361
Asp381
Lys285
Glu286
Val289
Lys271
Glu232
4. Drug-crizotinib -65.69 -60.5 -5.44 0
His361
Asp381
Lys285
Glu286
Val289
Ser500
Asp361
5. Andrographolide -76.06 -63.97 -12.09 0
Ser500
Lys285
Glu296
Val289
Asp381
Arg362
Table II: Interaction of andrographolide and the available drugs with 3OVV
S. No Compound Energy vdW H Bond Elec Interacting residues
1 Ligand-1sb -63.06 -50.88 -12.18 0
Thr51
Asn20
Tyr330
2 Drug-sorafenib -71.28 -64.58 -6.7 0
Thr51
Ala21
Gly52
Tyr330
3. Drug-imatinib -71.17 -55.69 -15.48 0
Asp75
Asn115
Glu334
Gly55
Arg56
Asp75
4. Drug-crizotinib -59.66 -55.4 -4.25 0
Tyr235
Arg137
His260
5. Andrographolide -71.35 -59.43 -6.7 0
Thr51
Asn20
Tyr330
Arg93
Trp30
Arg93
Arg190
Lys192
(a) (b) (c)
Fig. 4: 2D structures of anti-cancer drugs – (a) Sorafenib, (b) Imatinib and (c) CrozitinibSharmila et al. / In-Silico Analysis of Andrographolide…..……
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Table III: Interaction of andrographolide and the available drugs with 1M17
S. No Compound Energy vdW H Bond Elec Interacting residues
1 Ligand-erlotinib -62.37 -54.35 -8.02 0
Tyr740
Leu838
Glu673
Ala674
2 Drug-sorafenib -68.97 -59.06 -9.91 0
Asp813
Asp831
Phe699
Val702
3. Drug-imatinib -67.53 -60.26 -7.27 0
Met769
Asp831
Leu694
Val702
4. Drug-crizotinib -59.63 -52.93 -6.7 0 Pro890
Asp892
5. Andrographolide -58.19 -3.9 -19.19 0
Ser787
Leu838
Glu673
Gln788
Tyr789
Asp950
Glu961
(a) (b)
Fig. 5: (a) 2D structure of andrographolide, (b) 3D structure of andrographolide
(a) (b)
(c) (d)
Fig. 6: Results of the docked structures with the target
(a) Interaction of Crizotinib (CPK) and the ligand nilotinib (pink) with the active site residues of the target 3CS9. (b)Interaction of Imatinib (CPK) and the 
ligand nilotinib (pink) with the active site residues of the target 3CS9. (c )Interaction of Sorafenib (CPK) and the ligand nilotinib (pink) with the active site 
residues of the target 3CS9.(d)Interaction of Andrographolide (White) and the ligand nilotinib (pink) with the active site residues of the target 3CS9.Sharmila et al. / In-Silico Analysis of Andrographolide…..……
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(a) (b)
(c) (d)
Fig. 7: Results of the docked structures with the target
(a) Interaction of Crizotinib (white) and the ligand 1SB (pink) with the active site residues of the target 3OVV.(b) Interaction of Imatinib (white) and the ligand 
1SB (pink) with the active site residues of the target 3OVV. (c )Interaction of Sorafenib (CPK) and the ligand 1SB (pink) with the active site residues of the 
target 3OVV.(d) Interaction of Andrographolide (White) and the ligand 1SB (pink) with the active site residues of the target 3OVV.
(a) (b)
(c) (d)
Fig. 8: Results of the docked structures with the target 1M17
(a) Interaction of Crizotinib (CPK) and the ligand erlotinib (pink) with the active site residues of the target 1M17.(b)Interaction of Imatinib (CPK) and the 
ligand erlotinib (pink) with the active site residues of the target 1M17.(c) Interaction of Sorafenib (CPK) and the ligand erlotinib (pink) with the active site 
residues of the target 1M17.(d)Interaction of Andrographolide (CPK) and the ligand erlotinib (pink) with the active site residues of the target 1M17.Sharmila et al. / In-Silico Analysis of Andrographolide…..……
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Table IV: The drug- like parameters of Andrographolide
S. No Properties Value
1 Slog P 1.699
2 SlogD 1.699
3 mlogP 1.801
4 Molecular weight 350.458
5 Hydrogen Bond Donor 3.000
6 Hydrogen Bond Donor (M_No) 5.000
7 Topological polar Surface Area (T_PSA) 86.990
8 Rule of 5 0
9 Violation of Rule of 5 Nil
The compound andrographolide ehibited a fitness score of -
58.19  and  interacted  with  the  residues  Leu838,  Glu673, 
Ser787, Gln788, Tyr789, Asp950 and Glu961 at the active 
site.  Andrographolide  also  shows  good  interaction  and 
efficient score than the available drugs (Table III).
Drug likeliness and ADMET prediction
Lipinski’s rule of 5 states that a drug should be below 500 Da 
in its molecular  weight; Sholud  have log P (Ratio  of drug 
concentration in octanol: water) <5; H Bond donor < 5 and H 
bond acceptor <10.
From the Table IV, its inferred that Andrographolide had a 
molecular weight of 350.458 Da, the ratio of concentration of 
Andrographolide  in  octanol:water  (mlog  P)  is  1.801.  The 
compound  has  3  Hydrogen  Bond  donors  and  5  Hydrogen 
Bond acceptors (M_No). Andrographolide was found to obey 
all  the  parameters  of  Lipinski’s  Rule  of  5  and  has  drug 
likeliness. The  T-PSA (Topological Polar Surface  Area) is 
86.990.  Hence  its  accomplished  that  Andrographolide  can 
efficiently act as drug.
The  In-Silico studies  of  the  current  work  proves  the 
inhibition of 3 major targets of cancer by a natural compound 
Andrographolide.  Human  cAMP  dependent  protein  kinase 
(PDB ID-30VV) was efficiently inhibited by the compound 
andrographolide.  This  showed  minimal  energy  on  docking 
against  the  target  hence  suggesting  the  stability  of  the 
compound. It is also found to interact well at the active sites 
of the target. When compared with the already available anti-
cancer  drugs  and  enzyme  inhibitors,  andrographolide  was 
found to be efficient against the enzyme kinases. This was 
also found to obey the necessary parameters to act as drug 
especially  no  violations  in  the  Lipinski’s  Rule  of  5.  The 
interactions and fitness score of the compound and computed 
ADMET  properties  suggest  that  Andrographolide  can  be 
formulated as an anti cancer drug. 
Further  studies  can  be  extended  to  analyse  the 
pharmacokinetics and pharmacodynamics of andrographolide 
in cancer survivors.
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